Passa al contenuto
Merck
Tutte le immagini(1)

Documenti

F0175000

Flucytosine

European Pharmacopoeia (EP) Reference Standard

Sinonimo/i:

5-Fluorocytosine, 4-amino-5-fluoro-2(1H)-pyrimidinone, Flucytosine

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Formula empirica (notazione di Hill):
C4H4FN3O
Numero CAS:
Peso molecolare:
129.09
Beilstein:
127285
Numero MDL:
Codice UNSPSC:
41116107
ID PubChem:
NACRES:
NA.24

Grado

pharmaceutical primary standard

Famiglia di API

flucytosine

Produttore/marchio commerciale

EDQM

Punto di fusione

298-300 °C (dec.) (lit.)

applicazioni

pharmaceutical (small molecule)

Formato

neat

Temperatura di conservazione

2-8°C

Stringa SMILE

NC1=NC(=O)NC=C1F

InChI

1S/C4H4FN3O/c5-2-1-7-4(9)8-3(2)6/h1H,(H3,6,7,8,9)
XRECTZIEBJDKEO-UHFFFAOYSA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Flucytosine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Azioni biochim/fisiol

Nucleoside analog that has antifungal activities. 5-FC is deaminated by cytosine deaminase to product 5-fluorouracil, resulting in RNA miscoding. 5-Fluorocytosine inhibits DNA and RNA synthesis and interferes with ribosomal protein synthesis.

Confezionamento

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Altre note

Sales restrictions may apply.

Prodotti correlati

Pittogrammi

Health hazard

Avvertenze

Warning

Indicazioni di pericolo

Consigli di prudenza

Classi di pericolo

Repr. 2

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable


Choose from one of the most recent versions:

Certificati d'analisi (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 7

1 of 7

5-Fluorouracil ≥99% (HPLC), powder

Sigma-Aldrich

F6627

5-Fluorouracil

Amphotericin B Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1662

Amphotericin B

Fluconazole Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1160

Fluconazole

Ketoconazole 99.0-101.0% (EP, titration)

Sigma-Aldrich

K1003

Ketoconazole

vibrant-m

Y0000005

Amphotericin B

[Flucytosine - a classical partner for combination therapy].
Annemarie Polak
Mycoses, 45 Suppl 3, 31-33 (2003-04-15)
W L Whelan
Critical reviews in microbiology, 15(1), 45-56 (1987-01-01)
In terms of genetically determined susceptibility to the clinical antifungal agent 5-fluorocytosine (5-FC), Candida albicans may be homozygous sensitive (FCY/FCY), homozygous resistant (fcy/fcy), or heterozygous (fcy/FCY). Although heterozygotes are only slightly resistant, they occur at significant frequency among clinical strains
Angela Loyse et al.
The Journal of antimicrobial chemotherapy, 68(11), 2435-2444 (2013-06-22)
Current, widely accepted guidelines for the management of HIV-associated cryptococcal meningoencephalitis (CM) recommend amphotericin B combined with flucytosine (5-FC) for ≥2 weeks as the initial induction treatment of choice. However, access to flucytosine in Africa and Asia, where disease burden
J E Bennet
Annals of internal medicine, 86(3), 319-321 (1977-03-01)
Flucytosine is a systemic antifungal drug that is readily absorbed from the gastrointestinal tract. The most clearly documented therapeutic effect has been in cryptococcosis, candidiasis, and chromomycosis. An important limitation of the use of flucytosine in all three diseases has
A Vermes et al.
The Journal of antimicrobial chemotherapy, 46(2), 171-179 (2000-08-10)
Flucytosine (5-FC) is a synthetic antimycotic compound, first synthesized in 1957. It has no intrinsic antifungal capacity, but after it has been taken up by susceptible fungal cells, it is converted into 5-fluorouracil (5-FU), which is further converted to metabolites

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.